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Abstract
Background: Current influenza vaccines have reduced immunogenicity and are of uncertain efficacy in older adults. We
assessed the safety and immunogenicity of MVA-NP+M1, a viral-vectored influenza vaccine designed to boost memory T cell
responses, in a group of older adults.
Methods: Thirty volunteers (aged 50–85) received a single intramuscular injection of MVA-NP+M1 at a dose of 1?56108
plaque forming units (pfu). Safety and immunogenicity were assessed over a period of one year. The frequency of T cells
specific for nucleoprotein (NP) and matrix protein 1 (M1) was determined by interferon-gamma (IFN-c) ELISpot, and their
phenotypic and functional properties were characterized by polychromatic flow cytometry. In a subset of M1-specific CD8+
T cells, T cell receptor (TCR) gene expression was evaluated using an unbiased molecular approach.
Results: Vaccination with MVA-NP+M1 was well tolerated. ELISpot responses were boosted significantly above baseline
following vaccination. Increases were detected in both CD4+ and CD8+ T cell subsets. Clonality studies indicated that MVA-
NP+M1 expanded pre-existing memory CD8+ T cells, which displayed a predominant CD27+CD45RO+CD572CCR72
phenotype both before and after vaccination.
Conclusions: MVA-NP+M1 is safe and immunogenic in older adults. Unlike seasonal influenza vaccination, the immune
responses generated by MVA-NP+M1 are similar between younger and older individuals. A T cell-inducing vaccine such as
MVA-NP+M1 may therefore provide a way to circumvent the immunosenescence that impairs routine influenza vaccination.
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Introduction
Winter epidemics of influenza in the UK have caused 7,000–
25,000 deaths in the past decade (1999–2010) [1]. In addition,
influenza infection exerts pressure on healthcare systems and
results in substantial economic losses. The burden of disease in
developed countries disproportionately affects the elderly, with
approximately 90% of influenza-associated excess deaths occur-
ring among people aged 65 years and older [2]. Indeed, in those
over the age of 75 years, 2?5–8?1% of all deaths in the UK in the
last decade have been attributed to influenza virus infection [1].
Government-funded vaccination programmes for influenza
exist in many countries and include elderly individuals in their
target populations [3]. Unfortunately, the rates of seroprotection
and seroconversion following vaccination are significantly lower in
the elderly [4]. A recent systematic review found vaccine efficacy
was 59% in adults aged under 65 years, but no trials assessing
protection from laboratory-confirmed influenza have been con-
ducted in subjects aged over 65 years [5].
In the elderly, immunosenescence can negatively impact the
ability of the immune system to mount an effective immune
response to new pathogens and vaccines. Characteristics of
immunosenescence include: (i) a decrease in B cell function,
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which is thought to result from defective T cell help; (ii) thymic
involution and an associated reduction in naive T cell output; (iii)
expansion of selected memory T cell clones driven by persistent
viral infections such as CMV (reported to affect up to 90% of
elderly individuals) [6], and; (iv) increases in anergic CD282 T
cells and regulatory T cells [7]. Accordingly, there is an urgent
need for an effective influenza vaccine targeted to the require-
ments of the ageing immune system.
In addition to seasonal epidemics, influenza can cause
pandemics, typically following a viral antigenic shift. Therefore,
new vaccine candidates should ideally induce an element of cross-
strain (heterosubtypic) immunity [8]. One approach is to generate
high frequencies of CD8+ T cells directed against conserved
influenza antigens [9]. Viral-vectored vaccines elicit potent T cell
responses and therefore represent a promising strategy in this
regard. Modified Vaccinia virus Ankara (MVA) is a highly
attenuated strain of vaccinia virus in which viral replication is
blocked at a late stage of virion assembly [10]. Recombinant
MVAs are therefore efficient single-round expression vectors, and
have been used to prime or boost T cell responses to a diverse
range of pathogen-specific and tumour-derived antigens. Previ-
ously, we have shown that a recombinant MVA expressing the
nucleoprotein (NP) and matrix protein 1 (M1) sequences from a
H3N2 strain of influenza A (termed MVA-NP+M1), was safe and
immunogenic in young adults, significantly boosted T cell
responses to NP and M1 [11] and has a protective effect against
influenza challenge [12]. Such an approach may help to
circumvent the limitations of immunosenescence, by boosting
pre-existing memory T cell responses rather than by attempting de
novo priming from the naı¨ve lymphocyte pool. We have now
extended the Phase I trial into older adults, and demonstrate here
that MVA-NP+M1 is safe and highly immunogenic in this
population.
Methods
Study Design
This was a Phase I open-label, non-randomized vaccine trial.
The study was conducted at the Centre for Clinical Vaccinology
and Tropical Medicine, University of Oxford, Oxford, UK. The
clinical trial protocol and supporting CONSORT checklist are
available as Supplementary Information; see Protocol S1 and
Checklist S1. The trial protocol was approved within the UK by
the Medicines and Healthcare products Regulatory Agency and
the Gene Therapy Advisory Committee. The stated objectives of
the trial were to assess the safety and the cellular immune response
of a new influenza vaccine, MVA-NP+M1, when administered to
healthy volunteers. The trial was registered at www.clinicaltrials.
gov (identifier: NCT00942071).
Participants
Thirty subjects were enrolled in three stratified age groups: 50–
59 years, 60–69 years and 70+ years (10 volunteers per group).
Younger volunteers from our previous two clinical trials were used
for comparative purposes [11,12]. All volunteers were healthy
adults, resident in the Oxford area, with negative pre-vaccination
tests for HIV antibodies, hepatitis B surface antigen and hepatitis
C antibodies (see Supplementary Information: Protocol S1 for the
full list of inclusion and exclusion criteria). Written informed
consent was obtained in all cases. The planned sample size was 10
in each age group. This sample size should allow determination of
the magnitude of the outcome measures, especially of serious and
severe adverse events, rather than aiming to obtain statistical
significance.
MVA-NP+M1 Vaccine
The vaccine was described previously and consists of MVA
expressing the NP and M1 antigens from influenza A as a single
fusion protein [11].
Procedures
Volunteers were vaccinated on the day of enrolment with a
single intramuscular injection of MVA-NP+M1 at a dose of
1?56108 pfu into the deltoid region of the arm. Blood was taken
prior to the vaccination (week 0), and volunteers were observed for
a period of 1 hour following the vaccination. Volunteers were
given a digital thermometer, tape measure and symptom diary
card to record their daily temperature, injection site reactions and
solicited adverse events for 7 days. Two days after vaccination,
volunteers were reviewed in clinic and assessed for potential
adverse events. Volunteers were reassessed and blood samples
were taken at subsequent visits, which occurred at 1, 3, 8, 12, 24,
and 52 weeks post-vaccination.
Interferon-gamma ELISpot
Ex vivo interferon-gamma enzyme-linked immunosorbent spot
(IFN-c ELISpot) assays were performed using fresh peripheral
blood mononuclear cells (PBMC) as described previously [13].
Cells were washed and resuspended in RPMI 1640 containing
10% fetal calf serum, 100 IU/mL penicillin, 100 mg/mL strepto-
mycin (all Sigma), and 2 mM L-glutamine (Life Technologies)
(R10 medium). Peptides of 15–20 amino acids in length,
overlapping by 10 amino acids and spanning the whole of the
NP+M1 insert, were used to stimulate PBMC at a final
concentration of 10 mg/ml in 8 pools of 10 peptides. R10 medium
alone was used as a negative control, and a mixture of
phytohaemagglutinin (PHA; 10 mg/mL) and staphylococcal en-
terotoxin B (SEB; 1 mg/mL) was used as a positive control. Each
condition was assayed in triplicate using 26105 PBMC in a final
volume of 100 ml per well. ELISpot plates were incubated for 18–
20 hours at 37uC. Developed and dried ELISpot plates were
analysed with an AID ELISpot reader (AID Diagnostika). Results
are expressed as spot-forming units (SFU) per million PBMC,
calculated by subtracting the mean R10 negative control response
from the mean peptide pool response and summing the net
response for the 8 peptide pools. Plates were excluded if responses
were greater than 100 SFU/million PBMC in the R10 wells or less
than 1,000 SFU/million PBMC in the PHA/SEB wells.
Intracellular Cytokine Staining
Intracellular cytokine staining (ICS) was performed using two
different T cell staining panels at week 0, week 1 and week 3. The
first panel detected Th1-type cytokine (IFN-c, IL-2 and TNF)
production and CD107a mobilization. The second panel detected
CD107a mobilization, granzyme B expression, and the production
of IL-10 and IL-17. Reagent details are provided in Table S1.
Fresh PBMC (1–26106) were stimulated for 18 hr at 37uC with
either a single pool comprising of all the NP+M1 peptides at a final
concentration of 4 mg/ml, SEB (1 mg/ml) or medium alone. The
costimulatory monoclonal antibodies (mAbs) aCD28 and aCD49d
(1 mg/ml each; BD Pharmingen) were added to panel 1, and
aCD107a-PE-Cy5 (10 ml; eBioscience) was added to both panels.
After 2 hr, brefeldin A and monensin (both eBioscience) were
added. The cells were then washed, stained with the reagents listed
in Table S1 according to standard procedures and acquired using
an LSR II flow cytometer (BD Biosciences). Data were analysed
using FlowJo version 9?4 (Tree Star, Inc.). Unstained cells and
compensation beads (BD Biosciences) stained singly with the
MVA-NP+M1 in over 50s
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individual mAbs in each panel were used as controls to calculate
compensation. All mAbs were titrated for optimal staining.
Between 13,000 and 700,000 live, CD142CD192 lymphocyte
events were collected and analysed per condition.
TCR Clonotyping
Cryopreserved PBMC were thawed and labelled with PE-
conjugated GILGFVFTL/HLA A*0201 tetramer as described
previously [14], then washed and surface stained with the directly
conjugated mAbs listed in Table S1. Dead cells were excluded
using LIVE/DEADH Fixable Violet (Life Technologies), together
with CD14+ and CD19+ events, in a single ‘‘dump’’ channel.
Viable CD3+CD8+tetramer+ cells (918–5,000 per population)
were sorted at .98% purity using a customized FACSAria II flow
cytometer (BD Biosciences) and clonotypic analysis was conducted
using a template-switch anchored RT-PCR as described previ-
ously [14,15]. The IMGT nomenclature was used to assign TRB
gene usage [16].
Statistical Analysis
Statistical analysis was carried out using GraphPad Prism
software version 5?04. The non-parametric Mann-Whitney U-test
was employed to test for significant differences between groups of
volunteers, and the non-parametric Wilcoxon signed rank test was
used to test for significant differences between time points within
the same group of volunteers.
Results
Thirty volunteers were enrolled between Apr 06, 2010 and Nov
30, 2011 (Figure 1 and Table 1). Vaccination was well tolerated
and no serious vaccine-related clinical or laboratory adverse events
were observed. The frequency of local and systemic adverse
Figure 1. CONSORT flow diagram of the trial.
doi:10.1371/journal.pone.0048322.g001
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reactions is shown in Figure 2. All vaccine-related adverse events
were either mild or moderate in severity.
Figure 3a shows the T cell responses to the NP+M1 vaccine
insert as measured by IFN-c ELISpot. All assays were conducted
on fresh PBMCs as soon as they became available. As expected, T
cell responses to NP and M1 were detected prior to vaccination
with a median response of 188 SFU/million PBMC. These
responses increased to a median of 1,603 SFU/million PBMC one
week after vaccination, representing an 8.5-fold increase. When
the data were stratified for age (group 1= 50–59 years, group
2= 60–69 years, group 3= 70+ years), differences between the
groups became apparent. In particular, T cell responses to NP and
M1 remained significantly above baseline until week 52 for group
1, week 12 for group 2 and week 3 for group 3 (Figure 3b).
We previously vaccinated 15 healthy volunteers aged 18–45
years with MVA-NP+M1 using the same dose (1?56108 pfu) and
route of administration [12]. No significant differences in the
ELISpot responses were detected between the younger volunteers
(18–45 years) and the older volunteers (50+ years) either before
or after vaccination (Figure 3c), although there was a trend
towards higher responses in groups 1 and 2, and lower responses
in group 3.
Flow cytometry was used to determine antigen-specific cytokine
production (IFN-c, TNF, IL-2, IL-10 and IL-17), T cell
degranulation (CD107a mobilization) and granzyme B expression.
MVA-NP+M1 was shown to boost both CD4+ and CD8+ T cell
responses, and significant increases in IFN-c, IL-2 and TNF
production were observed in both populations at week 1 and week
3 post-vaccination (Figure 4). A significant increase in CD107a
mobilization was only detected for CD8+ T cells at week 3
(p = 0?004).
No increases in the antigen-specific production of IL-10, IL-17
or granzyme B were detected in either the CD4+ or CD8+ T cell
populations following vaccination (data not shown). However, as
reported previously [17] the production of granzyme B from
unstimulated CD8+ T cells was significantly elevated at week 1 in
the oldest age group (median= 57?8% of CD8+ T cells) compared
Figure 2. Frequency of local and systemic adverse events that were possibly, probably or definitely related to vaccination. (A)
Volunteers aged 50+ (n = 30). (B) Volunteers aged 18–45 (n = 15). For both age groups pain was the most frequently recorded local adverse event
followed by erythema. A similar pattern of systemic adverse events was observed in both age groups with the majority of solicited adverse events
occurring in 20–60% of individuals. For volunteers aged 18–45, 85% of adverse events were mild; for volunteers aged 50+, 87% of adverse events
were mild.
doi:10.1371/journal.pone.0048322.g002
Table 1. Demographic characteristics of volunteers
vaccinated in each cohort.
Group
Age range
(years)
Mean age
(years) Females
50–59 50–59 55?2 50%
60–69 60–66 63?3 70%
70+ 72–85 79?0 50%
doi:10.1371/journal.pone.0048322.t001
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to group 1 (median = 27?1%, p= 0.002) and group 2 (medi-
an = 29?3%, p= 0.0115). Non-specific granzyme B production by
CD8+ T cells was also significantly elevated in group 3 compared
to group 1 at week 3 (group 3= 45?9%, group 1= 25?2%;
p= 0.0113).
Figure 5 shows the frequency of polyfunctional CD4+ and CD8+
T cells detected by flow cytometry using panel 1. The percentage
of T cells with quadruple, triple and double functional outputs
detected in the CD4+ and CD8+ populations increased signifi-
cantly at week 1 and week 3 post-vaccination in group 1 (50–59
years). However, in groups 2 and 3, only the triple and double
functional cells in the CD4+ T cell population increased at the
same time points. In group 3, a significant increase in quadruple
and triple functional cells in the CD8+ T cell population was
detected at week 3 post-vaccination. The respective P values for
these comparisons (Wilcoxon signed rank test) are shown in Table
S2.
In further analyses, we examined the clonotypic composition of
CD8+ T cells specific for the HLA A*0201-restricted
GILGFVFTL epitope (M1, residues 58–66) using a template-
switch anchored RT-PCR to amplify all expressed TRB gene
products. A profound type IV bias was observed in these antigen-
specific CD8+ T cell populations, comprising strict TRBV19 usage
combined with a central XRSX motif in the CDR3 loop (Figure 6)
[18], consistent with previous reports [19,20]. To determine the
origins of these MVA-NP+M1 vaccine-expanded clonotypes, we
conducted similar studies in a separate cohort of volunteers. These
volunteers were aged 20–50 and had been vaccinated with either
56107 pfu intradermally or 2?56108 pfu intramuscularly [11].
Paired samples from day 0 (pre-vaccination) and day 7 (post-
vaccination) were available for three volunteers. In all cases, the
dominant clonotypes were identical at both time points, indicating
the expansion of pre-existing M1-specific memory CD8+ T cells
(Figure 7). However, the post-vaccination repertoires were more
Figure 3. Ex vivo IFN-c ELISpot responses to the vaccine insert. (A) Median and individual ex vivo IFN-c ELISpot responses from vaccinated
volunteers at baseline (week 0), and weeks 1, 3, 8, 12, 24, and 52. Significant differences between the pre- and post-vaccination time points were
detected using the Wilcoxon signed rank test: week 1 (p = 0?0001), week 3 (p = 0?0001), week 8 (p = 0?0001), and week 12 (p = 0?001). (B) Median ex
vivo IFN-c ELISpot responses to the NP+M1 insert stratified according to age: black bars = group 1 (50–59 years), white bars = group 2 (60–69 years),
and grey bars = group 3 (70+ years). Error bars indicate interquartile ranges. Significant differences between the pre- and post-vaccination time
points were detected using the Wilcoxon signed rank test as follows. Group 1: week 1 (p = 0?002), week 3 (p = 0?002), week 8 (p = 0?002), week 12
(p = 0?039), week 24 (p = 0?002), and week 52 (p = 0?0039). Group 2: week 1 (p = 0?002), week 3 (p = 0?002), week 8 (p = 0?002), and week 12
(p = 0?0371). Group 3: week 1 (p = 0?0039) and week 3 (p = 0?0195). Significant differences were also detected between groups using the Mann-
Whitney U-test, with responses in group 1 being higher than those in group 3 at week 3 (p = 0?043) and week 8 (p = 0?023). (C) Median and individual
ex vivo IFN-c ELISpot responses at week 1 and week 3 stratified according to age, and including a vaccinated cohort of younger (18–45 years)
volunteers.
doi:10.1371/journal.pone.0048322.g003
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Figure 4. IFN-c, IL-2, TNF and CD107a responses to the vaccine insert measured by flow cytometry. Production of IFN-c (A), IL-2 (B) and
TNF (C), and mobilization of CD107a (D), after background subtraction in CD3+CD4+ (black circles) and CD3+CD8+ (white circles) cell populations
stimulated with a single pool of peptides spanning the complete NP+M1 vaccine insert. Volunteers in group 3 were tested at weeks 0, 1, and 3.
Significant differences between pre- and post-vaccination time points were detected using the Wilcoxon signed rank test as follows: IFN-c CD4+,
week 1 (p = 0?0001) and week 3 (p = 0?0001); IFN-c CD8+, week 1 (p = 0?001) and week 3 (p = 0?0005); IL-2 CD4+, week 1 (p = 0.001) and week 3
(p = 0?0001); IL-2 CD8+, week 1 (p = 0?006) and week 3 (p = 0?03); TNF CD4+, week 1 (p = 0?002) and week 3 (p = 0?0003); TNF CD8+, week 1 (p = 0?0003)
and week 3 (p = 0?002); CD107a CD8+, week 3 (p = 0?004).
doi:10.1371/journal.pone.0048322.g004
Figure 5. Functional profile of T cell responses to the vaccine insert measured by flow cytometry. Mobilization of CD107a and
production of IFN-c, IL-2 and TNF after background subtraction in CD3+CD4+ (A) and CD3+CD8+ (B) cell populations stimulated with a single pool of
peptides spanning the complete NP+M1 vaccine insert. Median percentages of quadruple (black), triple (dark grey), double (light grey) and single
(white) functional cells are shown.
doi:10.1371/journal.pone.0048322.g005
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Figure 6. Phenotypic and clonotypic properties of M1-specific CD8+ T cells elicited by MVA-NP+M1. (A) Phenotype of vaccine-elicited
CD8+ T cells specific for the HLA A*0201-restricted M1-derived epitope GILGFVFTL (residues 58–66). Antigen-specific CD3+CD8+tetramer+ cells are
shown as coloured dots superimposed on bivariate plots showing the phenotypic distribution of the total CD8+ T cell population (grey density plots).
Response sizes were 1?48% (left panels) and 0?75% (right panels) with respect to the total CD8+ T cell population. (B) TRBV and TRBJ usage, CDR3
amino acid sequence and relative frequency of the GILGFVFTL-specific CD8+ T cell clonotypes contained within the antigen-specific populations
depicted in (A). Public clonotypes within the present dataset are colour-coded. Representative analyses are shown for volunteers in group 3 (70+
years).
doi:10.1371/journal.pone.0048322.g006
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polyclonal due to the presence of less frequent clonotypes in
greater numbers. This could reflect either de novo recruitment from
the naı¨ve pool or the expansion of clonotypes from the memory
pool with pre-vaccination frequencies below the limit of detection.
Notably, all sorted M1-specific CD8+ T cell populations displayed
a predominant CD27+CD45RO+CD572CCR72 memory phe-
notype (Figure 6 and data not shown). This phenotypic
homogeneity is consistent with the functional homogeneity
observed within the CD8+ compartment before and after
vaccination.
Discussion
Here, we report the ability of MVA-NP+M1 to boost influenza-
specific T cell responses in older adults. Recombinant MVA
vaccines are establishing a good reputation for safety, although the
majority of these data relate to younger individuals aged between
18–45 years. Our results with MVA-NP+M1 add to the
experience from cancer trials with MVA-5T4 that recombinant
MVA is safe in older adults [21]. Indeed, no severe or serious
adverse reactions were detected in our volunteers.
We also report that MVA-NP+M1 is highly immunogenic in
volunteers over the age of 50 years. In one quantitative review [4]
of trivalent inactivated influenza vaccines, rates of seroprotection
and seroconversion among those over 60 years old were four times
lower for H1 and B antigens, and twice as low for H3 antigens. In
addition, although not powered to detect declining efficacy with
age, an age stratification suggested a far lower efficacy rate for
those over 70 years [4]. Indeed, other studies have suggested that
vaccine efficacy appears to be as low as 30–40% in this age group
[22]. On an individual level, declines in immunological function
are unlikely to occur in a linear fashion (chronological age being
only a surrogate indicator of biological age) [23] However, on a
population level, declines in vaccine responsiveness are likely to be
observed as average age increases. Indeed, in the oldest age group
(70+ years), we observed a reduction in immunogenicity as
detected by ex-vivo IFN-c ELISpot compared to the youngest age
group (50–59 years), with significantly lower responses at 3 and 8
weeks post-vaccination. However, when the 3 age groups were
compared to a younger cohort of volunteers (18–45 years) who
received the same dose of the MVA-NP+M1 vaccine, no
significant differences were detected.
The functional characteristics of the cellular responses produced
by vaccination are potentially as important as magnitude [24].
Subsets of CD4+ and CD8+ T cells following vaccination with
MVA-NP+M1 are capable of secreting both TNF and IL-2, in
addition to IFN-c. Increases in the number of such polyfunctional
T cells have been associated with protective immunity in some
models of infection [25]. We show here that MVA-NP+M1
vaccination can also induce polyfunctional CD4+ and CD8+ T cell
responses in older adults, as determined by flow cytometric
assessment of CD107a mobilization and the production of IFN-c,
TNF and IL-2.
MVA-NP+M1 is designed to expand T cells that are already
present in the memory pool rather than prime naı¨ve T cells de novo.
Direct evidence for this mode of action comes from our
comparison herein of M1-specific TCR sequences before and
after vaccination. This provides a biological rationale for the use of
MVA-NP+M1 in elderly individuals due to the impairment of
thymic output with age. The absolute number of NP- and M1-
specific T cells required for host defence against influenza is not
known. However, the median ex vivo IFN-c ELISpot response
observed in the older volunteers peaked one week after vaccination
at 1,603 SFU/million PBMC, which represents an 8?5-fold
increase compared to the pre-vaccination response.
No vaccine-induced expression of granzyme B, IL-10 or IL-17
was detected in our cohort of older volunteers. However, we did
detect significantly higher non-specific levels of granzyme B
expression in group 3 (70+ years) compared to group 1 (50–59
years) at weeks 1 and 3 post-vaccination. It has been shown
previously that baseline granzyme B expression in CD8+ T cells is
higher in ageing volunteers and that these cells are associated with
a decreased ability to respond to stimulation with whole influenza
virus [17]. Degranulation and extracellular release of granzyme B
can also cause inflammation and extracellular granzyme B has
been implicated in increasing the risk of serious illness in the
elderly, including the risk of influenza induced cardiovascular
complications [26,27].
A high IFN-c:IL-10 ratio may be associated with protection
from influenza [28]. The median frequency of NP- and M1-
specific T cells that secreted IL-10 was low (below 0?006%) and
did not increase after vaccination, whereas there was a significant
increase in the number IFN-c-secreting T cells following
vaccination.
The memory phenotype of vaccine-induced CD8+ T cell
populations, at least for a subset of M1-specific cells, was
remarkably similar to that observed pre-vaccination. Indeed, a
marginal decrease in CD27 expression consistent with progressive
differentiation post-vaccination was the only detectable change
between the time points studied within individual volunteers (data
not shown). Thus, minimal differentiation-associated functional
variations would be expected. Interestingly, despite vaccine-
mediated expansion of pre-existing memory clonotypes, the
observed CD27+CD45RO+CD572CCR72 phenotype indicates
a lack of terminal differentiation and senescence [29]. This is
encouraging from the perspective that durable T cell immunity
may be feasible using this approach of boosting existing T cell
memory with an MVA-vectored vaccine.
MVA-vectored vaccines have the advantage that they can be
produced on the large scale required for widespread human
vaccination. The low level of polymorphism in NP and M1 across
influenza A strains means that a vaccine such as MVA-NP+M1
could provide T cell-mediated protection against all influenza A
subtypes.
In summary, we have shown that the novel influenza vaccine
candidate MVA-NP+M1 is safe and highly immunogenic in adults
over 50 years old. Both CD4+ and CD8+ memory T cell responses
are boosted, and have the capacity to secrete multiple cytokines.
Indeed, despite the apparent reduction in immune responsiveness
observed in the oldest volunteers in this study, there was still a
significant induction of IFN-c-secreting cells and a significant
increase in the proportion of CD4+ and CD8+ T cells capable of
triple cytokine production after vaccination. These enhanced T
cell responses could provide heterosubtypic T cell-based immunity
against influenza in the elderly.
Figure 7. Patterns of clonotype usage in M1-specific CD8+ T cell populations before and after vaccination with MVA-NP+M1. TRBV
and TRBJ usage, CDR3 amino acid sequence and relative frequency are shown for GILGFVFTL-specific CD8+ T cell clonotypes on day 0 (pre-
vaccination) and day 7 (post-vaccination). Public clonotypes within the present dataset are colour-coded. Non-public clonotypes present at both time
points within an individual are highlighted in bold type.
doi:10.1371/journal.pone.0048322.g007
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